Open

Essential Thrombocythemia (ET) medication study.

This research study is for people with essential thrombocythemia (ET) who need to start therapy to reduce blood counts or your currently therapy is not controlling your ET. In this study, we want to find out if a new drug can help normalize your blood count.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

If you decide to take part, you will receive medication in the form of a shot every two weeks. At each visit you will be asked questions about your health and the medications you're taking. You will also answer questionnaires. Blood draws for routine tests should be expected at every onsite visit. The study team will will perform an ultrasound to measure the size of your spleen, an eye exam, a chest X-ray, and an Echocardiogram (ECHO) of your heart. You have the option to take part in an optional bone marrow biopsy through your participation in the study.

Incentives

$75 stipend for each completed visit. , study medication, gas reimbursement as applicable, lodging reimbursement as applicable.

In-person visits:
33+

Phone or online visits:
27+

Total length of participation:
15 months with up to 3 years in follow up

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with essential thrombocythemia
You've never had treatment for your ET
You have good kidney and liver function

Not eligible if:

You've taken Interferon
You have heart disease or pulmonary hypertension
You have an autoimmune disease or compromised lung function
Use of any research medication within 4 weeks of the first dose of medication with this study.
You've used the medication ruxolitinib

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Comprehensive Cancer Center
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Brandi Reeves
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

23-0302

ClinicalTrials.gov

NCT05482971

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.